Shimpei Baba

Dr. Shimpei Baba

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2017 in Brain and Development
Verified
Journal Article
Closed access
PDF file
HYHaruna Yokoyama
Haruna Yokoyama
SBShimpei Baba
Shimpei Baba
JOJun Oyama
Jun Oyama
KMKengo Moriyama
Kengo Moriyama
TMTomohiro Morio
Tomohiro Morio

1 June 2019 in Pediatric Neurology
Verified
Journal Article
Closed access
SIShinji Itamura
Shinji Itamura
TOTohru Okanishi
Tohru Okanishi
MNMitsuyo Nishimura
Mitsuyo Nishimura
SKSotaro Kanai
Sotaro Kanai
SBShimpei Baba
Shimpei Baba
AFAyataka Fujimoto
Ayataka Fujimoto

18 June 2025 in Epilepsia Open
Verified
Journal Article
Open access
YTYoko Kobayashi Takahashi
Yoko Kobayashi Takahashi
KTKenshiro Tabata
Kenshiro Tabata
SBShimpei Baba
Shimpei Baba
ETEri Takeshita
Eri Takeshita
NSNoriko Sumitomo
Noriko Sumitomo
KIKen Inoue
Ken Inoue
A large number of cases with Dravet syndrome (DS) has been attributed to SCN1A loss of function (LOF), whereas SCN1A gain‐of‐function (GOF) causes early infantile developmental and epileptic encephalopathy (EIDEE) and familial hemiplegic migraine 3. We retrospectively analyzed 37 individuals with SCN1A pathogenic variants at our institute between January 2012 and October 2024 to investigate phenotype–function correlations. Variant functions were classified as LOF, GOF, or mixed, based on existing patch‐clamp data, paralog sodium channel experimental findings, and in silico prediction tools. Clinical characteristics, antiseizure medication (ASM) responses, and variant location were compared. Nine variants were novel. One variant with insufficient data for functional prediction was excluded. Of the 36 cases with predictable functions, five cases (14%) were classified as GOF/mixed (DS = 4, EIDEE = 1) and 31 (86%) as LOF (DS = 31). GOF/mixed‐DS had earlier epilepsy onset but otherwise resembled LOF‐DS. Sodium channel blocking ASMs (SCB‐ASMs) did not exacerbate seizures in GOF/mixed DS cases, with carbamazepine reducing seizures in one case. GOF/mixed variants clustered in the intracellular S6 segment, whereas LOF variants clustered in the S5–S6 pore loop. These findings highlight a potential GOF effect for certain DS cases, suggesting that SCB‐ASMs may be effective for GOF/mixed DS. This underscores the importance of functional characterization for tailored therapy, warranting further research to confirm and extend these results. Plain Language Summary: Dravet syndrome is a severe epilepsy that usually begins in infancy and is linked to changes in a gene called SCN1A . Most cases are caused by gene changes that reduce function, but in some cases, the gene may become overactive. In this study, we found that some patients with Dravet syndrome had these overactive changes and still showed typical symptoms. We found that people with overactive SCN1A function might respond differently to certain medications.

5 May 2021 in Epilepsia Open
Verified
Journal Article
Open access
PDF file
SBShimpei Baba
Shimpei Baba
TOTohru Okanishi
Tohru Okanishi
YHYoichiro Homma
Yoichiro Homma
TYTakeshi Yoshida
Takeshi Yoshida
TGTomohide Goto
Tomohide Goto
Ayataka FujimotoAyataka Fujimoto
Ayataka Fujimoto
Objectives: Long‐term adrenocorticotropic therapy (LT‐ACTH), which consisted of 2‐4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was to explore the efficacy of LT‐ACTH for preventing WS relapse, as well as the prevalence of its adverse events.Methods: This is a retrospective, nationwide, multicenter case series of patients with WS who underwent LT‐ACTH. Clinical information of the patients and protocol of LT‐ACTH were collected from participating institutes in this study. We defined clinical response to ACTH as achievement of hypsarrhythmia and epileptic spasms resolution. Patients who responded to daily ACTH injections were identified and assessed whether they experienced WS relapse during/after the weekly ACTH injection period. The outcome was measured by the nonrelapse rate at 24 months after daily ACTH injections using the Kaplan‐Meier method.Results: Clinical information of 16 children with WS was analyzed. The median age at LT‐ACTH initiation was 14.5 months (range: 7‐68 months). Thirteen (81%) patients had previously undergone conventional ACTH treatment. The LT‐ACTH regimens comprised a median of 16 days of daily injections (range: 11‐28 days) and 10 months of weekly injections (range: 3‐22 months). Seven patients experienced WS relapse during/after subsequent weekly ACTH period, and the nonrelapse rate at 24 months after daily injections was estimated at 60.6% (95% confidence interval: 32.3%‐80.0%). Height stagnation, hypertension, and irritability were observed; lethal adverse events were not reported.Significance: Our study firstly explored the efficacy of LT‐ACTH for preventing WS relapse. LT‐ACTH might be a treatment option for patients with relapsed or intractable WS; however, we note that our study is limited by its small sample size and the lack of an appropriate control group.

23 November 2020 in Neuropediatrics
Verified
Journal Article
Closed access
PDF file
SBShimpei Baba
Shimpei Baba
TOTohru Okanishi
Tohru Okanishi
KOKoichi Ohsugi
Koichi Ohsugi
RSRika Suzumura
Rika Suzumura
KNKeiko Niimi
Keiko Niimi
HEHideo Enoki
Hideo Enoki
We describe the efficacy of high-dose barbiturates and early administration of a parenteral ketogenic diet (KD) as initial treatments for acute status epilepticus (SE) in an 8-year-old girl with febrile infection-related epilepsy syndrome (FIRES). The patient was admitted to our hospital with refractory focal SE. Abundant epileptic discharges over the left frontal region were observed on electroencephalogram (EEG). Treatment with continuous infusion of thiamylal for 4 hours, increased incrementally to 40 mg/kg/h, successfully ended the clinical SE, and induced a burst-suppression coma. The infusion rate was then gradually decreased to 4 mg/kg/h over the next 12 hours. Parenteral KD was administered from days 6 to 21 of illness. Continuous infusion of thiamylal was switched to midazolam on day 10 without causing seizures or EEG exacerbations. The patient has remained seizure free in the 15 months since hospital discharge. The effectiveness of KD for the treatment of FIRES has attracted attention amongst clinicians, but KD treatment may need to last for 2 to 4 days before it can stop SE, a time period that could cause irreversible brain damage. Considering the severity of SE in our patient and the dose of barbiturates needed to treat it, we consider this case to have had a good clinical outcome. The results suggest that rapid termination of seizure using high-dose barbiturates in conjunction with early administration of parenteral KD could reduce the development of chronic epilepsy in patients with FIRES.

9 February 2021 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
AIAnna Ikawa
Anna Ikawa
Ayataka FujimotoAyataka Fujimoto
Ayataka Fujimoto
YAYoshifumi Arai
Yoshifumi Arai
YOYoshiro Otsuki
Yoshiro Otsuki
TNToshiki Nozaki
Toshiki Nozaki
HEHideo Enoki
Hideo Enoki
Epileptogenicity following brain insult depends on various factors including severity of the resulting lesion and extent of brain damage. We report a 54-year-old female patient who developed medically refractory epilepsy resulting from the interplay of pre-existing and post-insult pathologies. She presented with subarachnoid hemorrhage (SAH) due to a ruptured aneurysm and underwent clipping surgery. Seizures started 3 months post-operatively. MRI revealed cerebral ischemia and hemosiderin deposits in the left temporal lobes, and left hippocampal atrophy was suspected. As anti-seizure medications and vagus nerve stimulation failed to control her seizures, she underwent left temporal lobe resection and placement of a ventriculoperitoneal shunt for the post-operative complication of hydrocephalus. She remains seizure-free to date. Neuropathology revealed a previously undiagnosed focal cortical dysplasia (FCD) type 1a. Brain insult likely had a second hit effect in the late onset of epilepsy in this patient with pre-existing mild MCD, in whom secondary epilepsy can be attributed to the interplay of multiple underlying pathologies.